Akshaya Bio Inc. (Akshaya) is a privately held development stage biotechnology company located in Edmonton, Alberta, Canada.
Akshaya develops innovative therapeutics for infectious diseases and cancer. Akshaya's proprietary Chimigen® Platform Technology uses dendritic cell receptor-targeted chimeric molecules to develop a portfolio of biotherapeutic agents to meet major unmet medical needs such as treatments for chronic hepatitis B and hepatitis C virus infections, avian and swine influenza, alphavirus infections, malaria, HIV and cancer.
The Chimigen® Platform is used to produce Dendritic Cell Receptor-targeted Chimeric Molecules which have therapeutic as well as prophylactic applications. The vaccines produced in insect cells incorporate functional elements of both antigens and antibody. They mimic endogenous antigen presentation and elicit balanced cellular and humoral immune responses.